Commercial Viability
Little to none. NASA will have to heavily subsidise the work and it's applicable to astronauts and the lucky few for recreational space travel.
The
US patent doesn't cover Spaceflight Associated Neuro-ocular Syndrome (SANS), but given the mechanism is similar to reducing intracranial pressure, the only GLP-1 that will have data and regulatory approval will be Presendin.
The benefit to Invex
Hopefully the company provides some guidance to the ASX if this is material.
The FDA have a
close relationship with NASA in terms of a MOU, but yet have
rarely used data from microgravity to support the efficacy of a drug in a New Drug Application(NDA).
In order to attract a premium valuation from Big Pharma, we need to show a pipeline of possible future indications for Presendin - so sponsored research for Presendin in SANS builds out the pipeline and de-risks its mechanism of reducing intracranial pressure.
